<DOC>
	<DOCNO>NCT02395822</DOCNO>
	<brief_summary>A phase II trial CD3/CD19 deplete , IL-15 activate , donor natural killer ( NK ) cell adults subcutaneous IL-15 give preparative regimen treatment relapse refractory acute myelogenous leukemia ( AML ) . The primary objective study potential efficacy NK cell IL-15 achieve complete remission maintain safety .</brief_summary>
	<brief_title>MT2014-25 : Haplo NK With SQ IL-15 Adult Relapsed Refractory AML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion Criteria ( Recipient ) : Meets ONE follow disease criterion : 1 . Primary AML induction failure : CR 2 induction attempt 2 . Relapsed AML Secondary AML ( MDS treatment relate ) : CR 1 cycle standard reinduction therapy 3 . AML relapse &gt; 2 month transplant : No reinduction require , 1 reinduction cycle allow . 4 . Relapsed AML patient &gt; 60 year age 1 cycle standard chemotherapy require either follow criterion meet : Relapse within 6 month last chemotherapy BM blast count &lt; 30 % within 10 day start protocol therapy Available related HLAhaploidentical donor ( age 14 75 year ) least Class I serologic type A &amp; B locus Karnofsky Performance Status â‰¥ 60 % Patients must adequate organ within 14 day ( 28 day pulmonary cardiac ) study registration Able prednisone immunosuppressive medication least 3 day prior NK cell infusion ( exclude preparative regimen premedications ) . Agrees use contraception prior study entry duration study participation . Exclusion Criteria ( Recipient ) : Biphenotypic acute leukemia . Transplant &lt; 60 day prior study enrollment . Active autoimmune disease . History severe asthma Uncontrolled intercurrent illness New progressive pulmonary infiltrates screen chest xray chest CT scan evaluate bronchoscopy Pleural effusion large enough detectable chest xray . Pregnant woman History HIV , active chronic hepatitis B , hepatitis C HTLVI infection Known hypersensitivity study agent use Received investigational drug within 14 day study registration . Known active CNS involvement . Criteria For Initial Donor Selection : Related donor ( sibling , parent , offspring , parent offspring HLA identical sibling ) . 1475 year age . At least 40 kilogram body weight . In general good health determine evaluate medical provider . HLAhaploidentical donor/recipient match least Class I serologic type A &amp; B locus . Not pregnant . Able willing undergo apheresis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>